新石文化(01740.HK)年度純利跌61.5%至2483.2萬元
格隆匯3月27日丨新石文化(01740.HK)公佈,截至2019年12月31日止年度,公司實現收益人民幣2.13億元(單位下同),同比增長38.0%;毛利6142.3萬元,同比減少23.32%;母公司擁有人應占溢利2483.2萬元,同比減少61.5%;每股盈利3.31分。
收益增長主要由於授出電視劇播放權許可的收入增加所致。毛利下跌主要由於自制電視劇《共和國血脈》的低毛利所致,源自(i)客户中國中央電視台根據其政策及播放時間表,調整劇集播放的集數及(ii)《共和國血脈》引致的生產成本高,以符合中國中央電視台的質素標準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.